SCHEMBL29967965

SCHEMBL29967965

Cc1n[nH]c2ncc(CN3CCc4ccc(C(=O)Nc5cc(C(=O)NCCN(C)C)cc(C(F)(F)F)c5)cc43)cc12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DDR2 Q16832 14/20 0.39
▸ DDR1 Q08345 13/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ CASP7 P55210 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ABL1 P00519 8/20 0.39
▸ BCR P11274 3/20 0.39
▸ BRAF P15056 3/20 0.38
▸ KIT P10721 3/20 0.38
▸ NTRK3 Q16288 3/20 0.37
▸ NTRK1 P04629 2/20 0.37
▸ NTRK2 Q16620 2/20 0.37
▸ PDGFRB P09619 2/20 0.36
▸ KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27081850 1.00 DDR2 (0.39) DDR2DDR1KDM4EALDH1A1GLA
SCHEMBL27288843 0.94 KDM4E (0.38) DDR2DDR1KDM4EALDH1A1GLA
SCHEMBL27082011 0.86 DDR2 (0.45) DDR2DDR1ABL1BCRKIT
SCHEMBL29967998 0.86 DDR2 (0.45) DDR2DDR1ABL1BCRKIT
SCHEMBL29968231 0.85 WNT1 (0.42) DDR2DDR1ABL1BCRBRAF
SCHEMBL27081627 0.85 WNT1 (0.42) DDR2DDR1ABL1BCRBRAF
SCHEMBL29967389 0.84 DDR2 (0.51) DDR2DDR1ABL1BCRBRAF
SCHEMBL29968090 0.84 DDR2 (0.56) DDR2DDR1ABL1BCRKIT
SCHEMBL27081787 0.84 DDR2 (0.56) DDR2DDR1ABL1BCRKIT
SCHEMBL27081794 0.84 DDR2 (0.51) DDR2DDR1ABL1BCRBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP claimed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP claimed
WO-2022200577-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-09-29 — — WO claimed
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 DDR2 2/4885DDR1 1/4885KDM4E 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback